Glaxo: New product lines will reverse falling sales
Pharmaceutical giant GlaxoSmithKline has said it has a health portfolio of new products in the pipe-line that will reverse their falling sales.
Turnover fell by 2% in the three months to the end of 2011, leaving full-year sales down 3% at $43.5bn.
In common with many big players in the industry, Glaxo faces problems inventing new drugs to replace those whose patents have expired.
